ATE435872T1 - Anti-interleukin-1 rezeptor antikörper und deren verwendung - Google Patents

Anti-interleukin-1 rezeptor antikörper und deren verwendung

Info

Publication number
ATE435872T1
ATE435872T1 AT04764984T AT04764984T ATE435872T1 AT E435872 T1 ATE435872 T1 AT E435872T1 AT 04764984 T AT04764984 T AT 04764984T AT 04764984 T AT04764984 T AT 04764984T AT E435872 T1 ATE435872 T1 AT E435872T1
Authority
AT
Austria
Prior art keywords
interleukin
receptor antibodies
antibodies
receptor
Prior art date
Application number
AT04764984T
Other languages
English (en)
Inventor
Ilse Bartke
Francis Carr
Anthony Chizzonite
Elsie Eugui
Georg Fertig
Anita Hamilton
Martin Lanzendoerfer
Petra Rueger
Ralf Schumacher
Theresa Truitt
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42778436&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE435872(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE435872T1 publication Critical patent/ATE435872T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT04764984T 2003-09-10 2004-09-09 Anti-interleukin-1 rezeptor antikörper und deren verwendung ATE435872T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50168103P 2003-09-10 2003-09-10
EP03029659 2003-12-23
PCT/EP2004/010047 WO2005023872A1 (en) 2003-09-10 2004-09-09 Antibodies against interleukin-1 receptor and uses thereof

Publications (1)

Publication Number Publication Date
ATE435872T1 true ATE435872T1 (de) 2009-07-15

Family

ID=42778436

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04764984T ATE435872T1 (de) 2003-09-10 2004-09-09 Anti-interleukin-1 rezeptor antikörper und deren verwendung

Country Status (13)

Country Link
US (2) US20050118169A1 (de)
EP (1) EP1664121B1 (de)
JP (1) JP2007527230A (de)
AR (1) AR045614A1 (de)
AT (1) ATE435872T1 (de)
AU (1) AU2004270390A1 (de)
BR (1) BRPI0414259A (de)
CA (1) CA2538319A1 (de)
MX (1) MXPA06002728A (de)
NZ (1) NZ545761A (de)
RU (1) RU2369617C2 (de)
TW (1) TWI295672B (de)
WO (1) WO2005023872A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2336324A2 (de) 2005-03-25 2011-06-22 National Research Council of Canada Verfahren zur Isolation von löslichen Polypeptiden
TWI320788B (en) 2005-05-25 2010-02-21 Hoffmann La Roche Method for the purification of antibodies
WO2007059782A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
KR20080077237A (ko) 2005-12-01 2008-08-21 도만티스 리미티드 인터루킨 1 수용체 타입 1에 결합하는 경쟁적 도메인 항체포맷
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
CN101460522B (zh) * 2006-04-11 2014-07-23 弗·哈夫曼-拉罗切有限公司 糖基化抗体
AU2008279550B2 (en) * 2007-06-21 2012-08-09 Angelica Therapeutics, Inc. Modified toxins
ES2401820T3 (es) 2007-07-17 2013-04-24 F. Hoffmann - La Roche Ag Filtración de flujo tangencial variable
EP2268297A4 (de) * 2008-02-29 2011-11-16 Angelica Therapeutics Inc Modifizierte toxine
US8298533B2 (en) * 2008-11-07 2012-10-30 Medimmune Limited Antibodies to IL-1R1
WO2010080463A1 (en) * 2008-12-18 2010-07-15 Imclone Llc Antibody humanization
KR101536388B1 (ko) 2009-10-19 2015-07-22 에프. 호프만-라 로슈 아게 비-교차반응성 항-ＩｇＧ 항체
KR102071834B1 (ko) 2009-10-26 2020-01-30 에프. 호프만-라 로슈 아게 글리코실화된 면역글로불린의 제조 방법
RU2603284C2 (ru) 2010-08-17 2016-11-27 Ф.Хоффманн-Ля Рош Аг АНТИТЕЛА ПРОТИВ IgG1 ЧЕЛОВЕКА
PE20131411A1 (es) 2010-10-05 2013-12-16 Hoffmann La Roche Anticuerpos contra la tweak humana y usos de los mismos
EP2697260A1 (de) 2011-04-15 2014-02-19 Merck Patent GmbH Anti-il-1r1-inhibitoren zur verwendung bei krebs
ES2548215T3 (es) 2011-10-05 2015-10-14 F. Hoffmann-La Roche Ag Proceso para la producción de anticuerpos de la glicoforma G1
FI3091029T3 (fi) 2011-10-31 2023-03-20 Hoffmann La Roche Anti-il13-vasta-aineformulaatioita
RU2014139546A (ru) * 2012-03-27 2016-05-20 Дженентек, Инк. Методы прогнозирования, диагностики и лечения идиопатического легочного фиброза
JP2016519651A (ja) 2013-03-15 2016-07-07 アンジェリカ セラピューティックス，インク． 改質された毒素
EP3004368B1 (de) 2013-05-29 2019-09-18 F.Hoffmann-La Roche Ag Quantitative steuerung von sialylierung
CA2911965C (en) 2013-07-05 2018-06-19 F. Hoffmann-La Roche Ag Process for the mono- and bi-sialylation of glycoproteins employing n-terminally truncated beta-galactoside alpha-2,6-sialyltransferase mutants
EP4252629A3 (de) 2016-12-07 2023-12-27 Biora Therapeutics, Inc. Verfahren, vorrichtungen und systeme zur detektion des magen-darm-trakts
US20200315540A1 (en) 2016-12-14 2020-10-08 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an il-1 inhibitor
UY37651A (es) 2017-03-31 2018-10-31 Swedish Orphan Biovitrum Ab Publ Polipéptido de unión al il-1r-i
CA3066918A1 (en) 2017-06-12 2018-12-20 Bluefin Biomedicine, Inc. Anti-il1rap antibodies and antibody drug conjugates
KR20210095165A (ko) 2018-11-19 2021-07-30 프로제너티, 인크. 바이오의약품으로 질환을 치료하기 위한 방법 및 디바이스

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) * 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) * 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) * 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (de) * 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hämoglobin, das an ein Poly(alkenylenoxid) gebunden ist
US4791192A (en) * 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5204244A (en) * 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) * 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US6511665B1 (en) * 1987-11-25 2003-01-28 Immunex Corporation Antibodies to interleukin-1 receptors
US6652854B2 (en) * 2000-08-08 2003-11-25 Immunex Corporation Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L

Also Published As

Publication number Publication date
EP1664121B1 (de) 2009-07-08
JP2007527230A (ja) 2007-09-27
US20090191187A1 (en) 2009-07-30
RU2006111579A (ru) 2007-10-27
TWI295672B (en) 2008-04-11
US20050118169A1 (en) 2005-06-02
WO2005023872A1 (en) 2005-03-17
AU2004270390A1 (en) 2005-03-17
RU2369617C2 (ru) 2009-10-10
MXPA06002728A (es) 2006-06-06
AR045614A1 (es) 2005-11-02
EP1664121A1 (de) 2006-06-07
BRPI0414259A (pt) 2006-11-07
TW200513261A (en) 2005-04-16
CA2538319A1 (en) 2005-03-17
NZ545761A (en) 2008-10-31

Similar Documents

Publication Publication Date Title
ATE435872T1 (de) Anti-interleukin-1 rezeptor antikörper und deren verwendung
ATE456581T1 (de) Antikörper gegen il21-rezeptor und deren verwendung
DE602004031988D1 (de) Antikörper gegen insulinartigen Wachstumsfaktor-I-Rezeptor und deren Verwendung
ATE446953T1 (de) P2x7-rezeptorantagonisten und deren verwendung
DE60230868D1 (de) Criptoblockierende antikörper und deren verwendung
CY2016016I1 (el) Ανθρωπινο αντισωμα αντι-υποδοχεα επιδερμικου αυξητικου παραγοντα
DE602005023639D1 (de) Chinuclidinderivate und deren verwendung als muscarin-m3-rezeptor-antagonisten
DE602004021904D1 (de) Gyraseinhibitoren und deren verwendungen
ATE470675T1 (de) Immunoglobulinvarianten und deren verwendungen
DE60112322D1 (de) Aminothiazole und deren verwendung als adenosinrezeptorantagonisten
ATE381335T1 (de) 2-cyanopyrrolopyrimidine und deren pharmazeutische verwendung
DK2662390T3 (da) Interferon alpha receptor 1-antistoffer og anvendelse heraf
DE60328087D1 (de) Aryl substituierte pyrimidine und deren verwendung
DE602005003186D1 (de) Fluorkopolymer und dessen Verwendung
ATE511507T1 (de) Piperidinylcarbonylpyrrolidine und deren verwendung als melanocortinagonisten
ATE414690T1 (de) Fluoro substituierte cycloalkanindole und deren verwendung als prostaglandin d2 rezeptor antagonisten
ATE412013T1 (de) Anti-osteopontin-antikörper und dessen verwendung
ATE428710T1 (de) Substituierte phenylaminothiazole und ihre verwendung
DE602004031607D1 (de) Propylenpolymerzusammensetzung und verwendung davon
DE602005009988D1 (de) Härtbare Zusammensetzung und deren Verwendung
ATE396185T1 (de) Substituierte 4-alkyl- und 4- alkanoylpiperidinderivate und deren verwendung als neurokininantagonisten
DE602004027354D1 (de) SUBSTITUIERTE 8y-PYRIDINYLDIHYDROSPIROiCYCLOALKYL PYRIMIDOi1,2-A PYRIMIDIN-6-ON- UND 8y-PYRIMIDINYLDIHYDROSPIROiCYCLOALKYL PYRIMIDOi1,2-A PYRIMIDIN-6-ONDERIVATE UND DEREN VERWENDUNG BEI NEURODEGENERATIVEN KRANKHEITEN
FI20060188A (fi) Modifioidut IL-4-muteiinin reseptorin antagonistit
DE60114413D1 (de) Substituierte 1-aminoalkyl-lactame und deren verwendung als muscarinrezeptor-antagonisten
DE60336266D1 (de) Substituierte 1-piperidin-4-yl-pyrrolidin-3-yl-piperazinderivate und deren verwendung als neurokinin antagonisten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties